Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

Full Year 2024 Results Key Financial Results Revenue: UK£31.4b (up 3.5% from FY 2023). Net ...

In June, 75 years of manufacturing history will come to an end in the town when pharmaceutical giant GSK closes its factory at Canal Foot. The history of the pharmaceutical industry in the town goes ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Among those with chronic medical conditions, a third (33 percent) either had no concerns about developing shingles or were ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

The pharmaceutical firm has followed several companies which have dropped diversity goals amid pressure from President Donald ...

Research analysts at Zacks Research cut their Q1 2025 EPS estimates for shares of GSK in a note issued to investors on ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts ...